Overview
- Wakefit’s Rs 1,288.89 crore issue is priced at Rs 185–195 and is open for bids from Dec 8–10, with allotment slated for Dec 11 and a tentative listing on Dec 15 on BSE and NSE.
- The offer combines a Rs 377.18 crore fresh issue with an offer-for-sale of about Rs 912 crore, implying a market value near Rs 6,300–6,400 crore at the top end.
- Wakefit raised about Rs 580 crore from 33 anchor investors, and the issue is skewed to institutions with a 75% QIB, 15% NII and 10% retail allocation.
- Wakefit’s FY25 total income reached Rs 1,305.43 crore with EBITDA of Rs 90.83 crore, but the net loss widened to Rs 35 crore, drawing mixed brokerage views that range from avoid to long-term subscribe.
- Grey-market trackers peg Wakefit’s GMP near Rs 36 (about 18% over the top band) versus Corona Remedies’ roughly Rs 290 (about 27%), with Corona’s fully OFS IPO at Rs 1,008–1,062 backed by reported FY25 PAT of Rs 149 crore.